TCRX
TCRX
NASDAQ · Biotechnology

Tscan Therapeutics Inc

$0.33
-0.01 (-2.21%)
As of Sep 29, 3:31 PM ET ·
Financial Highlights (FY 2026)
Revenue
5.40M
Net Income
-67,772,477
Gross Margin
—
Profit Margin
-1,256.8%
Rev Growth
-8.6%
D/E Ratio
0.26
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 59.6% 59.6%
Operating Margin -1,315.4% -1,183.8% -11.3% -9.5%
Profit Margin -1,256.8% -1,194.0% -12.6% -11.2%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 5.40M 5.91M 16.16M 15.23M
Gross Profit — — 9.63M 9.08M
Operating Income -70,967,750 -69,911,312 -1,821,663 -1,449,059
Net Income -67,772,477 -66,763,604 -2,032,977 -1,710,895
Gross Margin — — 59.6% 59.6%
Operating Margin -1,315.4% -1,183.8% -11.3% -9.5%
Profit Margin -1,256.8% -1,194.0% -12.6% -11.2%
Rev Growth -8.6% -8.6% -2.0% -5.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 2.41M 2.41M 15.92M 17.53M
Total Equity 9.11M 9.11M 24.83M 23.68M
D/E Ratio 0.26 0.26 0.64 0.74
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -69,433,069 -72,199,447 -2,828,117 -2,426,513
Free Cash Flow — — -1,769,464 -1,134,231